| Literature DB >> 29603227 |
Yuki Kiyozumi1, Masaaki Iwatsuki1, Junji Kurashige1, Yoko Ogata1, Kohei Yamashita1, Yuki Koga1, Tasuku Toihata1, Yukiharu Hiyoshi1, Takatsugu Ishimoto1, Yoshifumi Baba1, Yuji Miyamoto1, Naoya Yoshida1, Kazuyoshi Yanagihara2, Koshi Mimori3, Hideo Baba1.
Abstract
Peritoneal dissemination is the most common metastatic pattern in advanced gastric cancer (GC) and has a very poor prognosis. However, its molecular mechanism has not been elucidated. Our study investigated genes associated with peritoneal dissemination of GC. We performed combined expression analysis of metastatic GC cell lines and identified Procollagen-lysine, 2-oxoglutarate 5-dioxygenase2 (PLOD2) as a potential regulator of peritoneal dissemination. PLOD2 is regulated by hypoxia-inducible factor-1 (HIF-1) and mediates extracellular matrix remodeling, alignment, and mechanical properties. We analyzed PLOD2 expression immunohistochemically in 179 clinical samples, and found high PLOD2 expression to be significantly associated with peritoneal dissemination, leading to poor prognosis. In an in vivo-collected metastatic cell line, downregulation of PLOD2 by siRNA reduced invasiveness and migration. Hypoxia upregulated PLOD2 mediated by HIF-1, and promoted invasiveness and migration. After exposure to hypoxia, a cell line transfected with siPLOD2 exhibited significantly suppressed invasiveness and migration, despite high HIF-1 expression. These findings indicate that PLOD2 is a regulator of, and candidate therapeutic target for peritoneal dissemination of GC. Although peritoneal dissemination of GC has a very poor prognosis, its molecular mechanism has not been elucidated. We identified PLOD2 regulated by HIF-1 as a potential regulator of peritoneal dissemination of GC. Finally, we showed that PLOD2 promotes cell invasiveness and migration in GC under hypoxia and lead to peritoneal dissemination of GC.Entities:
Keywords: HIF-1; PLOD2; gastric cancer; hypoxia; peritoneal dissemination
Mesh:
Substances:
Year: 2018 PMID: 29603227 DOI: 10.1002/ijc.31410
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396